Chemokine ligand 2 genetic variants, serum monocyte chemoattractant protein-1 levels, and the risk of coronary artery disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 7, 2010, Pages 1460-1466

  Van Wijk, Diederik F ^a   Van Leuven, Sander I ^a   Sandhu, Manjinder S ^a,b,c   Tanck, Michael W ^a   Hutten, Barbara A ^a   Wareham, Nicholas J ^d   Kastelein, John J P ^a   Stroes, Erik S G ^a   Khaw, Kay Tee ^b,c   Boekholdt, S Matthijs ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d MRC EPIDEMIOLOGY UNIT   (United Kingdom)

Author keywords

atherosclerosis; CCL2; coronary artery disease; monocyte chemoattractant protein 1; single nucleotide polymorphism

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CASE CONTROL STUDY; CCL2 GENE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; GENE; GENETIC RISK; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CORONARY ARTERY DISEASE; ENGLAND; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 77953960348     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.205526     Document Type: Article

References (24)

1. Bacon K, Baggiolini M, Broxmeyer H, Horuk R, Lindley I, Mantovani A, Maysushima K, Murphy P, Nomiyama H, Oppenheim J, Rot A, Schall T, Tsang M, Thorpe R, Van Damme J, Wadhwa M, Yoshie O, Zlotnik A, Zoon K. Chemokine/chemokine receptor nomenclature. J Interferon Cy-tokine Res. 2002;22:1067-1068.
2. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610-621.
3. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol. 2008;28:1897-1908.
4. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoat-tractant protein-1 in human atheromatous plaques. J Clin Invest. 1991; 88:1121-1127.
5. Yu X, Dluz S, Graves DT, Zhang L, Antoniades HN, Hollander W, Prusty S, Valente AJ, Schwartz CJ, Sonenshein GE. Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci USA. 1992;89: 6953-6957.
6. Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM, Wildevuur CR, Eijsman L, Trouwborst A, Hack CE. Activation of the complement system during and after cardiopulmo-nary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96: 3542-3548.
7. McDermott DH, Yang Q, Kathiresan S, Cupples LA, Massaro JM, Keaney JF, Jr., Larson MG, Vasan RS, Hirschhorn JN, O'Donnell CJ, Murphy PM, Benjamin EJ. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation. 2005;112: 1113-1120.
8. Souverein OW, Zwinderman AH, Tanck MW. Estimating haplotype effects on dichotomous outcome for unphased genotype data using a weighted penalized log-likelihood approach. Hum Hered. 2006;61: 104-110.
9. Tanck MW, Klerkx AH, Jukema JW, De Knijff P, Kastelein JJ, Zwin-derman AH. Estimation of multilocus haplotype effects using weighted penalised log-likelihood: analysis of five sequence variations at the cho-lesteryl ester transfer protein gene locus. Ann Hum Genet. 2003;67: 175-184.
10. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, McCabe CH, Cannon CP, Braunwald E. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003;107:690-695.
11. Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M, Paloscia L, Materazzo G, D'Annunzio E, Conti P, Chiarelli F, Cuccurullo F, Mezzetti A. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol. 2001;21:327-334. (Pubitemid 32199112)
12. Oshima S, Ogawa H, Hokimoto S, Nakamura S, Noda K, Saito T, Soejima H, Takazoe K, Ishibashi F, Yasue H. Plasma monocyte chemoat-tractant protein-1 antigen levels and the risk of restenosis after coronary stent implantation. Jpn Circ J. 2001;65:261-264.
13. Deo R, Khera A, McGuire DK, Murphy SA, Meo Neto Jde P, Morrow DA, de Lemos JA. Association among plasma levels of monocyte che-moattractant protein-1, traditional cardiovascular risk factors, and sub-clinical atherosclerosis. J Am Coll Cardiol. 2004;44:1812-1818.
14. Ortlepp JR, Vesper K, Mevissen V, Schmitz F, Janssens U, Franke A, Hanrath P, Weber C, Zerres K, Hoffmann R. Chemokine receptor (CCR2) genotype is associated with myocardial infarction and heart failure in patients under 65 years of age. J Mol Med. 2003;81:363-367.
15. Mosedale DE, Smith DJ, Aitken S, Schofield PM, Clarke SC, McNab D, Goddard H, Gale CR, Martyn CN, Bethell HW, Barnard C, Hayns S, Nugent C, Panicker A, Grainger DJ. Circulating levels of MCP-1 and eotaxin are not associated with presence of atherosclerosis or previous myocardial infarction. Atherosclerosis. 2005;183:268-274.
16. Gonzalez E, Rovin BH, Sen L, Cooke G, Dhanda R, Mummidi S, Kulkarni H, Bamshad MJ, Telles V, Anderson SA, Walter EA, Stephan KT, Deucher M, Mangano A, Bologna R, Ahuja SS, Dolan MJ, Ahuja SK. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci USA. 2002;99:13795-13800.
17. Tabara Y, Kohara K, Yamamoto Y, Igase M, Nakura J, Kondo I, Miki T. Polymorphism of the monocyte chemoattractant protein (MCP-1) gene is associated with the plasma level of MCP-1 but not with carotid intima-media thickness. Hypertens Res. 2003;26:677-683.
18. Cho ML, Kim JY, Ko HJ, Kim YH, Kim WU, Cho CS, Kim HY, Hwang SY. The MCP-1 promoter-2518 polymorphism in Behcet's disease: correlation between allele types, MCP-1 production and clinical symptoms among Korean patients. Autoimmunity. 2004;37:77-80.
19. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, Sone T, Tanaka M, Yokota M. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med. 2002; 347:1916-1923.
20. Simeoni E, Winkelmann BR, Hoffmann MM, Fleury S, Ruiz J, Kappen-berger L, Marz W, Vassalli G. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J. 2004;25:1438-1446.
21. Szalai C, Duba J, Prohaszka Z, Kalina A, Szabo T, Nagy B, Horvath L, Csaszar A. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD): coincidence of elevated Lp (a) and MCP-1-2518 G/G genotype in CAD patients. Atherosclerosis. 2001;158:233-239.
22. Alonso-Villaverde C, Coll B, Parra S, Montero M, Calvo N, Tous M, Joven J, Masana L. Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation. 2004;110:2204-2209.
23. Boekholdt SM, Peters RJ, Day NE, Luben R, Bingham SA, Wareham NJ, Hack CE, Reitsma PH, Khaw KT. Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study. Am J Med. 2004;117: 390-397.
24. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N. STrengthening the REporting of Genetic Association Studies (STREGA)\an extension of the STROBE statement. Genet Epidemiol. 2009;33:581-598.